RecruitingNCT07316062
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
Sponsor
AstraZeneca
Enrollment
3,000 participants
Start Date
Apr 29, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Stage I-III at initial NSCLC diagnosis
- Aged ≥18 years at first diagnosis of NSCLC
- Timeframe of NSCLC diagnosis:
- For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027
Exclusion Criteria4
- NSCLC is not the primary cancer diagnosis
- Patients with a recent history of other tumor or concurrent other tumor
- Patients participating in interventional clinical trials at time of initial diagnosis
- Patients with positive pregnancy status at the time of diagnosis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07316062
Related Trials
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NCT074623776 locations
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
NCT074890663 locations
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
NCT053632807 locations
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT075196556 locations
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT0668279310 locations